ArticleClinical and translational science2022

Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study.

Stefano Mazza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.